MCID: BRN048
MIFTS: 40

Brain Stem Cancer

Categories: Cancer diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Brain Stem Cancer

MalaCards integrated aliases for Brain Stem Cancer:

Name: Brain Stem Cancer 12 54 15
Brain Stem Neoplasms 45 74
Malignant Neoplasm of Brain Stem 12
Malignant Neoplasm of Brainstem 12
Brain Stem Neoplasms, Primary 74
Malignant Tumor of Brainstem 12
Neoplasm of Adult Brain Stem 12
Primary Brain Stem Neoplasm 12
Primary Brain Stem Tumor 12
Tumor of Adult Brainstem 12
Neoplasm of Brain Stem 12
Tumor of the Brainstem 12
Brain Stem Neoplasm 17
Brain Stem--Cancer 74
Brain Stem Tumors 56

Classifications:



External Ids:

Disease Ontology 12 DOID:4203
ICD9CM 36 191.7
MeSH 45 D020295
SNOMED-CT 69 93726004
ICD10 34 C71.7

Summaries for Brain Stem Cancer

MalaCards based summary : Brain Stem Cancer, also known as brain stem neoplasms, is related to brain stem glioma and brain stem medulloblastoma. An important gene associated with Brain Stem Cancer is NES (Nestin), and among its related pathways/superpathways are Activation of cAMP-Dependent PKA and TGF-Beta Pathway. The drugs Temozolomide and Carboplatin have been mentioned in the context of this disorder. Affiliated tissues include brain, bone and endothelial.

Related Diseases for Brain Stem Cancer

Graphical network of the top 20 diseases related to Brain Stem Cancer:



Diseases related to Brain Stem Cancer

Symptoms & Phenotypes for Brain Stem Cancer

Drugs & Therapeutics for Brain Stem Cancer

Drugs for Brain Stem Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 103)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Temozolomide Approved, Investigational Phase 2,Phase 1 85622-93-1 5394
2
Carboplatin Approved Phase 2 41575-94-4 10339178 38904 498142
3
Thiotepa Approved, Investigational Phase 2 52-24-4 5453
4
Lenograstim Approved, Investigational Phase 2 135968-09-1
5
Gefitinib Approved, Investigational Phase 1, Phase 2 184475-35-2 123631
6
Etoposide Approved Phase 2 33419-42-0 36462
7
Celecoxib Approved, Investigational Phase 2 169590-42-5 2662
8
Bevacizumab Approved, Investigational Phase 2 216974-75-3
9
Irinotecan Approved, Investigational Phase 2 100286-90-6, 97682-44-5 60838
10
Cisplatin Approved Phase 2 15663-27-1 2767 441203 84093
11
Dasatinib Approved, Investigational Phase 2 302962-49-8 3062316
12
Miconazole Approved, Investigational, Vet_approved Phase 2,Phase 1 22916-47-8 4189
13
Everolimus Approved Phase 2,Phase 1 159351-69-6 70789204 6442177
14
Sirolimus Approved, Investigational Phase 2,Phase 1 53123-88-9 46835353 5284616 6436030
15
Pemetrexed Approved, Investigational Phase 2 150399-23-8, 137281-23-3 60843 446556
16
Dexamethasone Approved, Investigational, Vet_approved Phase 2 50-02-2 5743
17
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 2 1177-87-3
18
Hydroxocobalamin Approved Phase 2 13422-51-0 15589840 11953898
19
Atezolizumab Approved, Investigational Phase 2 1380723-44-3
20
Methylcobalamin Approved, Experimental, Investigational Phase 2 13422-55-4
21
leucovorin Approved Phase 2 58-05-9 143 6006
22
Vorinostat Approved, Investigational Phase 1, Phase 2 149647-78-9 5311
23
Cetuximab Approved Phase 2 205923-56-4 56842117 2333
24
Nicotinamide Approved, Investigational Phase 2 98-92-0 936
25
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
26
Cyanocobalamin Approved, Nutraceutical Phase 2 68-19-9 44176380
27
Niacin Approved, Investigational, Nutraceutical Phase 2 59-67-6 938
28
Camptothecin Experimental Phase 2 7689-03-4
29
Nimotuzumab Investigational Phase 2 780758-10-3, 828933-61-3
30
Cobalamin Experimental Phase 2 13408-78-1 6857388
31
Imetelstat Investigational Phase 2 868169-64-6
32 O(6)-benzylguanine Phase 2
33 Alkylating Agents Phase 2,Phase 1
34 Antineoplastic Agents, Alkylating Phase 2,Phase 1
35 Immunologic Factors Phase 2,Phase 1
36 Immunosuppressive Agents Phase 2,Phase 1
37 Angiogenesis Modulating Agents Phase 2
38 Anti-Infective Agents Phase 2,Phase 1
39 Anti-Bacterial Agents Phase 2,Phase 1
40 Angiogenesis Inhibitors Phase 2
41 Protein Kinase Inhibitors Phase 1, Phase 2,Phase 2
42 Topoisomerase Inhibitors Phase 2
43 Anti-Inflammatory Agents Phase 2,Phase 1
44 Analgesics Phase 2,Phase 1
45 Etoposide phosphate Phase 2
46 Antirheumatic Agents Phase 2,Phase 1
47 Analgesics, Non-Narcotic Phase 2,Phase 1
48 Anti-Inflammatory Agents, Non-Steroidal Phase 2,Phase 1
49 Antineoplastic Agents, Phytogenic Phase 2
50 Peripheral Nervous System Agents Phase 2,Phase 1

Interventional clinical trials:

(show all 26)
# Name Status NCT ID Phase Drugs
1 O6-Benzylguanine and Temozolomide in Treating Young Patients With Recurrent or Progressive Gliomas or Brain Stem Tumors Completed NCT00275002 Phase 2 O6-benzylguanine;temozolomide
2 Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Glioblastoma Multiforme or Brain Stem Tumors Completed NCT00002619 Phase 2 carboplatin;thiotepa
3 Thalomid and Carboplatin for the Treatment of Pediatric Brain Stem Glioma Completed NCT00179881 Phase 2 Carboplatin;Thalomid
4 Gefitinib and Radiation Therapy in Treating Children With Newly Diagnosed Gliomas Completed NCT00042991 Phase 1, Phase 2 gefitinib
5 ANGIOCOMB Antiangiogenic Therapy for Pediatric Patients With Diffuse Brain Stem and Thalamic Tumors Completed NCT01756989 Phase 2 Thalidomide, etoposide, celecoxib
6 Bevacizumab and Irinotecan in Treating Young Patients With Recurrent, Progressive, or Refractory Glioma, Medulloblastoma, Ependymoma, or Low Grade Glioma Completed NCT00381797 Phase 2 Irinotecan Hydrochloride
7 Irinotecan in Combination With Cisplatin in Pediatric Patients With Unfavorable Prognosis Gliomas Completed NCT01574092 Phase 2 Combination of two marketed drugs (irinotecan and cisplatin)
8 Nimotuzumab in Combination With Radio-chemotherapy for the Treatment of Brainstem Tumor in Children Recruiting NCT02672241 Phase 2 Nimotuzumab;Temozolomide
9 Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication Recruiting NCT02233049 Phase 2 Erlotinib;Everolimus;Dasatinib
10 Study of Dasatinib in Combination With Everolimus for Children and Young Adults With Gliomas Harboring PDGFR Alterations Recruiting NCT03352427 Phase 2 Dasatinib;Everolimus
11 Atezolizumab in Combination With Carboplatin Plus Pemetrexed in Chemotherapy-naïve Patients With Asymptomatic Brain Metastasis Recruiting NCT03526900 Phase 2 Atezolizumab
12 Vorinostat and Radiation Therapy Followed by Maintenance Therapy With Vorinostat in Treating Younger Patients With Newly Diagnosed Diffuse Intrinsic Pontine Glioma Active, not recruiting NCT01189266 Phase 1, Phase 2 Vorinostat
13 External Beam Radiation Therapy and Cetuximab Followed by Irinotecan and Cetuximab for Children and Young Adults With Newly Diagnosed Diffuse Pontine Tumors and High-Grade Astrocytomas Active, not recruiting NCT01012609 Phase 2
14 Imetelstat Sodium in Treating Younger Patients With Recurrent or Refractory Brain Tumors Terminated NCT01836549 Phase 2 imetelstat sodium
15 A Phase I Study of ABT-888, an Oral Inhibitor of Poly(ADP-ribose) Polymerase and Temozolomide in Children With Recurrent/Refractory CNS Tumors Completed NCT00994071 Phase 1 Temozolomide;ABT-888
16 p28 in Treating Younger Patients With Recurrent or Progressive Central Nervous System Tumors Completed NCT01975116 Phase 1 azurin-derived cell-penetrating peptide p28
17 Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas, Diffuse Intrinsic Pontine Gliomas, Hypermutated Brain Tumors, Ependymoma or Medulloblastoma Recruiting NCT02359565 Phase 1
18 Convection-Enhanced Delivery of 124I-8H9 for Patients With Non-Progressive Diffuse Pontine Gliomas Previously Treated With External Beam Radiation Therapy Recruiting NCT01502917 Phase 1
19 Entinostat in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors Recruiting NCT02780804 Phase 1 Entinostat
20 Phase I Study of Mebendazole Therapy for Recurrent/Progressive Pediatric Brain Tumors Recruiting NCT02644291 Phase 1 Mebendazole
21 Phase I Rindopepimut After Conventional Radiation in Children w/ Diffuse Intrinsic Pontine Gliomas Terminated NCT01058850 Phase 1
22 Study of Vioxx and Radiation Therapy for Brainstem Glioma Terminated NCT00038389 Phase 1 Vioxx
23 A Phase I Study of IMC-A12 in Combination With Temsirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors Withdrawn NCT01182883 Phase 1 IMC-A12;Temsirolimus
24 Vegetative Monitoring During Brainstem-associated Surgery Recruiting NCT03666507
25 Molecular Analysis of Samples From Patients With Diffuse Intrinsic Pontine Glioma and Brainstem Glioma Recruiting NCT01106794
26 Study of Brain Tumors (Tectal Tumors) Using Magnetic Resonance Imaging Withdrawn NCT00229814

Search NIH Clinical Center for Brain Stem Cancer

Cochrane evidence based reviews: brain stem neoplasms

Genetic Tests for Brain Stem Cancer

Anatomical Context for Brain Stem Cancer

MalaCards organs/tissues related to Brain Stem Cancer:

42
Brain, Bone, Endothelial, Bone Marrow, Spinal Cord

Publications for Brain Stem Cancer

Articles related to Brain Stem Cancer:

# Title Authors Year
1
Orthostatic hypotension following surgery on brain-stem neoplasms: report of two cases. ( 4414953 )
1974

Variations for Brain Stem Cancer

Expression for Brain Stem Cancer

Search GEO for disease gene expression data for Brain Stem Cancer.

Pathways for Brain Stem Cancer

Pathways related to Brain Stem Cancer according to GeneCards Suite gene sharing:

(show all 19)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.23 H3F3A H3F3B HIST1H3B HIST1H3G PDGFB
2
Show member pathways
13.2 H3F3A H3F3B HIST1H3B HIST1H3G PDGFB
3
Show member pathways
13.15 H3F3A H3F3B HIST1H3B HIST1H3G PDGFB
4
Show member pathways
12.96 BSG H3F3A H3F3B HIST1H3B HIST1H3G PDGFB
5
Show member pathways
12.81 H3F3A H3F3B HIST1H3B HIST1H3G
6
Show member pathways
12.71 H3F3A H3F3B HIST1H3B HIST1H3G
7
Show member pathways
12.68 H3F3A H3F3B HIST1H3B HIST1H3G
8
Show member pathways
12.54 H3F3A H3F3B HIST1H3B HIST1H3G
9
Show member pathways
12.38 H3F3A H3F3B HIST1H3B HIST1H3G
10
Show member pathways
12.2 H3F3A H3F3B HIST1H3B HIST1H3G
11
Show member pathways
11.98 H3F3A H3F3B HIST1H3B HIST1H3G
12 11.89 H3F3A H3F3B HIST1H3B HIST1H3G
13 11.75 H3F3A H3F3B HIST1H3B HIST1H3G
14
Show member pathways
11.55 H3F3A H3F3B HIST1H3B HIST1H3G
15 11.48 NES PDGFB
16
Show member pathways
11.41 H3F3A H3F3B HIST1H3B HIST1H3G
17 11.03 H3F3A H3F3B
18 10.94 HIST1H3B HIST1H3G
19 10.34 H3F3A H3F3B HIST1H3B HIST1H3G

GO Terms for Brain Stem Cancer

Cellular components related to Brain Stem Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.88 H3F3A H3F3B HIST1H3B HIST1H3G PDGFB TMPRSS11D
2 extracellular exosome GO:0070062 9.85 BSG H3F3A H3F3B HIST1H3B HIST1H3G TMPRSS11D
3 protein-containing complex GO:0032991 9.73 H3F3A H3F3B HIST1H3B HIST1H3G
4 chromosome GO:0005694 9.62 H3F3A H3F3B HIST1H3B HIST1H3G
5 nucleosome GO:0000786 9.46 H3F3A H3F3B HIST1H3B HIST1H3G
6 Barr body GO:0001740 9.26 H3F3A H3F3B
7 nuclear chromosome GO:0000228 9.26 H3F3A H3F3B HIST1H3B HIST1H3G
8 nuclear nucleosome GO:0000788 8.92 H3F3A H3F3B HIST1H3B HIST1H3G

Biological processes related to Brain Stem Cancer according to GeneCards Suite gene sharing:

(show all 24)
# Name GO ID Score Top Affiliating Genes
1 cellular protein metabolic process GO:0044267 9.81 H3F3A H3F3B HIST1H3B HIST1H3G
2 blood coagulation GO:0007596 9.78 H3F3A H3F3B HIST1H3B HIST1H3G
3 nucleosome assembly GO:0006334 9.67 H3F3A H3F3B HIST1H3B HIST1H3G
4 embryo implantation GO:0007566 9.63 BSG H3F3A H3F3B
5 single fertilization GO:0007338 9.62 H3F3A H3F3B
6 regulation of megakaryocyte differentiation GO:0045652 9.62 H3F3A H3F3B HIST1H3B HIST1H3G
7 negative regulation of protein binding GO:0032091 9.61 NES PDGFB
8 protein heterotetramerization GO:0051290 9.61 HIST1H3B HIST1H3G
9 oogenesis GO:0048477 9.59 H3F3A H3F3B
10 DNA replication-dependent nucleosome assembly GO:0006335 9.58 HIST1H3B HIST1H3G
11 interleukin-7-mediated signaling pathway GO:0038111 9.58 HIST1H3B HIST1H3G
12 nucleus organization GO:0006997 9.57 H3F3A H3F3B
13 DNA replication-independent nucleosome assembly GO:0006336 9.56 H3F3A H3F3B
14 regulation of gene silencing by miRNA GO:0060964 9.56 H3F3A H3F3B HIST1H3B HIST1H3G
15 muscle cell differentiation GO:0042692 9.55 H3F3A H3F3B
16 regulation of gene silencing GO:0060968 9.54 HIST1H3B HIST1H3G
17 pericentric heterochromatin assembly GO:0031508 9.52 H3F3A H3F3B
18 regulation of centromere complex assembly GO:0090230 9.49 H3F3A H3F3B
19 chromatin silencing at rDNA GO:0000183 9.46 H3F3A H3F3B HIST1H3B HIST1H3G
20 negative regulation of chromosome condensation GO:1902340 9.43 H3F3A H3F3B
21 telomeric heterochromatin assembly GO:0031509 9.4 H3F3A H3F3B
22 brain development GO:0007420 9.3 NES
23 telomere organization GO:0032200 9.26 H3F3A H3F3B HIST1H3B HIST1H3G
24 negative regulation of gene expression, epigenetic GO:0045814 9.02 H3F3A H3F3B HIST1H3B HIST1H3G PPM1D

Molecular functions related to Brain Stem Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cadherin binding GO:0045296 9.43 BSG HIST1H3B HIST1H3G
2 protein heterodimerization activity GO:0046982 9.35 H3F3A H3F3B HIST1H3B HIST1H3G PDGFB
3 RNA polymerase II core promoter sequence-specific DNA binding GO:0000979 9.16 H3F3A H3F3B
4 nucleosomal DNA binding GO:0031492 8.92 H3F3A H3F3B HIST1H3B HIST1H3G

Sources for Brain Stem Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....